Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
1-15 of 189
Cracking the Migraine Code: How AI May Transform Diagnosis and Treatment
On the Frontlines of MigraineCracking the Migraine Code: How AI May Transform Diagnosis and Treatment
Challenges and Opportunities in Migraine Management
On the Frontlines of MigraineChallenges and Opportunities in Migraine Management
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Endogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems
On the Frontlines of MigraineEndogenous Pathways in Migraine Care: Harnessing the Body's Natural Systems
How Daily Light Habits Influence Migraine in Adolescents
On the Frontlines of MigraineHow Daily Light Habits Influence Migraine in Adolescents
Rethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
NeuroFrontiersRethinking Schizophrenia Guidelines: Why It’s Time to Incorporate Novel Mechanisms
- advertisement
Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
NeuroFrontiersBridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
NeuroFrontiersBridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions
Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
On the Frontlines of SchizophreniaNegative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden
Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
NeuroFrontiersAdvancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
- advertisement
Understanding Schizophrenia: The Role of Neurotransmission and Inflammation
NeuroFrontiersUnderstanding Schizophrenia: The Role of Neurotransmission and Inflammation
Harnessing AI to Predict and Prevent Schizophrenia Relapse
NeuroFrontiersHarnessing AI to Predict and Prevent Schizophrenia Relapse
Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
NeuroFrontiersEngaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach
